within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01E_OtherCardiacPreparations.C01EB07_Fructose16Diphosphate;

model Fructose16Diphosphate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 2500 / 1000000,
    adminCount = 1,
    Vd = 0.008,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fructose16Diphosphate</td></tr><tr><td>ATC code:</td><td>C01EB07</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>2500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fructose 1,6-diphosphate is a phosphorylated carbohydrate compound that has been investigated as a cardioprotective agent in experimental and limited clinical settings, particularly for myocardial ischemia or reperfusion injury. It is not currently an approved drug for routine clinical use.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies available. Parameters are estimated based on physicochemical properties, indirect preclinical reports, and analogous simple carbohydrates.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01EB07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fructose16Diphosphate;
